Baxter International Inc (BAX)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE
Market Cap: $13.21B
Last updated: Nov 17, 2026 at 4:41 PM ET
Baxter International Inc (BAX) Statistics
Baxter International (BAX) has a market cap of $13.21B and an enterprise value of $19.84B. Its return on invested capital of 0.41% compares with a 7.67% median across 10 similar companies. Its trailing P/E of 13.3x is below its 10-year median of 23.0x.
Total Valuation
Enterprise value is 50.15% above the market cap, as debt exceeds cash.
| Market Cap | $13.21B |
|---|---|
| Enterprise Value | $19.84B |
| Latest price (Nov 17, 2026) | $25.77 |
Key Dates
The next earnings report is expected on Feb 10, 2027, covering the quarter ending Dec 31, 2026. The next ex-dividend date is Nov 27, 2026.
| Next Earnings Date | Feb 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 29, 2026 |
| Next Ex-Dividend Date | Nov 27, 2026 |
| Next Payment Date | Jan 4, 2027 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 1.1x and 2.0x. Its year-end P/E ranged from 8.4x to 26.0x from 2016 to 2025.
| P/E Ratio | 13.3x |
|---|---|
| Forward P/E | 12.1x |
| P/S Ratio | 1.1x |
| Forward P/S | 1.1x |
| P/B Ratio | 2.0x |
| P/FCF Ratio | 11.7x |
| P/OCF Ratio | 8.1x |
| PEG Ratio | 2.0 |
Enterprise Valuation
Counting debt and cash, the company is valued at 19.6x EBITDA and 17.5x free cash flow.
| EV / Sales | 1.7x |
|---|---|
| EV / EBITDA | 19.6x |
| EV / EBIT | 320.0x |
| EV / FCF | 17.5x |
Price Statistics
The stock is up 39.71% over 52 weeks and trades 4.97% above its 50-day average.
| Beta (1Y) | 1.05 |
|---|---|
| 52-Week Change | +39.71% |
| 1-Month Change | +3.10% |
| 3-Month Change | -3.25% |
| 6-Month Change | +40.69% |
| 5-Year Change | -70.87% |
| 10-Year Change | -51.67% |
| Total Return (1Y) | +39.93% |
| Total Return (3Y CAGR) | -8.43% |
| Total Return (5Y CAGR) | -18.53% |
| Return vs SPY (1Y) | +30.62% |
| Max Drawdown (1Y) | -29.02% |
| Max Drawdown (3Y) | -62.45% |
| Sharpe Ratio (1Y) | 0.84 |
| Correlation with SPY (1Y) | 0.34 |
| 50-Day Average | $24.55 |
| 200-Day Average | $21.69 |
| 52-Week Range | $15.72 to $29.99 |
| RSI (14 Days) | 53.8 |
| Average Volume (20 Days) | 7.15M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.79x current liabilities, and total debt is 1.32x shareholder equity.
| Current Ratio | 1.79x |
|---|---|
| Quick Ratio | 1.19x |
| Debt / Equity | 1.32x |
| Debt / EBITDA | 8.46x |
| Debt / FCF | 7.56x |
Returns and Efficiency
Return on invested capital is 0.41% over the last 12 months, against a 5-year average of -1.36%.
| Return on Equity (ROE) | -11.12% |
|---|---|
| Return on Assets (ROA) | -3.72% |
| Return on Invested Capital (ROIC) | 0.41% |
| Return on Capital Employed (ROCE) | 0.40% |
| ROE (5Y Average) | -4.06% |
| ROA (5Y Average) | -0.50% |
| ROIC (5Y Average) | -1.36% |
| Asset Turnover | 0.57x |
| Inventory Turnover | 3.56x |
| Receivables Turnover | 6.38x |
| Cash Conversion Cycle | 113 days |
Scores
BAX has an Altman Z-Score of 2.43, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 2.43 |
|---|---|
| Altman Z Zone | Grey |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $11.61B over the last 12 months is up 5.33% from the 12 months before.
| Revenue | $11.61B |
|---|---|
| Revenue Growth (YoY) | +5.33% |
| Gross Profit | $3.49B |
| Operating Income | -$221.00M |
| Pretax Income | -$187.00M |
| Net Income | -$723.00M |
| EBITDA | $1.02B |
| EBIT | $62.00M |
| Reported EPS (TTM) | $1.94 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 33.49% of the $19.41B in total assets.
| Cash and Equivalents | $1.98B |
|---|---|
| Total Debt | $8.60B |
| Net Debt | $6.63B |
| Net Debt Per Share | $12.82 |
| Working Capital | $3.02B |
| Shareholder Equity | $6.50B |
| Book Value Per Share | $12.58 |
| Tangible Book Value | -$2.30B |
| Total Assets | $19.41B |
| Total Liabilities | $12.94B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $503.00M of capital spending, operating cash flow left $1.14B of free cash flow.
| Operating Cash Flow | $1.64B |
|---|---|
| Capital Expenditures | $503.00M |
| Free Cash Flow | $1.14B |
| FCF Per Share | $2.20 |
| Depreciation and Amortization | $955.00M |
| Dividends Paid | $102.00M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -1.90%, against a 5-year average of -2.59%.
| Gross Margin | 30.09% |
|---|---|
| Operating Margin | -1.90% |
| Pretax Margin | -1.61% |
| Net Margin | -6.23% |
| EBITDA Margin | 8.76% |
| EBIT Margin | 0.53% |
| FCF Margin | 9.79% |
| Gross Margin (5Y Average) | 36.34% |
| Operating Margin (5Y Average) | -2.59% |
| Net Margin (5Y Average) | -0.44% |
Growth
Revenue grew 3.79% a year over 3 years, and EPS fell 13.44% a year.
| Revenue Growth (3Y CAGR) | +3.79% |
|---|---|
| Revenue Growth (5Y CAGR) | -0.75% |
| EPS Growth (3Y CAGR) | -13.44% |
| EPS Growth (5Y CAGR) | -5.98% |
| FCF Growth (3Y CAGR) | -26.44% |
| FCF Growth (5Y CAGR) | -22.12% |
| Book Value Per Share Growth (2Y CAGR) | -15.17% |
Dividends and Yields
BAX pays out 1.26% of earnings as dividends.
| Dividend Per Share (Annual) | $0.04 |
|---|---|
| Dividend Yield | 0.16% |
| Payment Schedule | Quarterly |
| Dividend Growth (3Y CAGR) | -23.25% |
| Dividend Growth (5Y CAGR) | -11.45% |
| Payout Ratio | 1.26% |
| FCF Payout Ratio | 8.97% |
| Earnings Yield | 7.52% |
| FCF Yield | 8.54% |
| Buyback Yield | -0.18% |
| Shareholder Yield | 0.59% |
Stock Splits
The last split was a 2-for-1 forward split on May 31, 2001.
| Last Split Date | May 31, 2001 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 2:1 |
Peer Position
Against 11 similar companies, BAX has the 11th highest P/E and the lowest P/S.
P/E RatioPeer median 20.7x
P/S RatioPeer median 2.8x
ROICPeer median 7.67%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +9.05%
Dividend YieldPeer median 0.00%
| P/E Ratio | 13.3x vs 20.7x median |
|---|---|
| P/S Ratio | 1.1x vs 2.8x median |
| ROIC | 0.41% vs 7.67% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +5.33% vs +9.05% median |
| Dividend Yield | 0.16% vs 0.00% median |
Analyst Forecast
Consensus estimates put revenue growth at 3.13% and EPS growth at -5.07% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +3.13% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | -5.07% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About BAX
What is BAX's market cap?
Baxter International has a market cap of $13.21B. Its enterprise value, which adds debt and subtracts cash, is $19.84B.
What is BAX's P/E ratio?
Baxter International has a trailing P/E ratio of 13.3x and a forward P/E of 12.1x.
How many shares of BAX are outstanding?
Baxter International has 517.00M shares outstanding. The count is up 0.58% from a year earlier.
Does BAX pay a dividend?
Yes. Baxter International pays $0.04 a share a year, a dividend yield of 0.16%.
How much debt does BAX have?
Baxter International has $8.60B of total debt and $1.98B of cash and equivalents, a net debt position of $6.63B.
BAX pages: Overview, Dividends, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors